International data agrees

Omicron is less severe and natural immunity works Link to free download of my 2 textbooks Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California Background The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global dissemination, accounting for most infections in the United States by December 2021. November 30, 2021 to January 1, 2022, Delta v Omicron Using S gene target failure (SGTF) (99.7%) Hospital admission Lengths of hospital stay Hospital admissions associated with new-onset respiratory symptoms Intensive care unit (ICU) admission Mechanical ventilation Mortality Group 1, omicron N = 52,297, cases with Omicron variant infections Hospital admissions, 235 (0.5%) Mean follow-up, 5.5 days 88 admitted ITU, 7 Ventilated, 0 Deaths, 1 Length of hospital stay, 3.4 days (70%) less than delta Group 2, non – omicron (delta) N = 16,982, cases with Delta variant infections Hospital admissions, 222 (1.3%) Mean follow-up, 15.8 days 189 admitted ITU, 23 Ventilated, 11 Deaths, 14 Also Omicron variant infection, reduced risk of hospitalization across age and comorbidity categories Risk of symptomatic hospitalization was markedly reduced among cases who had tested positive for SARS-CoV-2 infection ≥90 days prior Intrinsically less severe infection Less severe in vaccinated and unvaccinated Evidence for a reduction in severe outcomes among vaccinated cases with both Delta and Omicron variant infections in our study suggests substantial public health benefits from continued COVID-19 vaccination. Dutch data Common cold protection Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts Cross-reactive immune responses to SARS-CoV-2 52 COVID-19 household contacts We enumerate the frequency of specific T cells Spike, nucleocapsid, membrane, envelope and ORF1, that cross-react with human endemic coronaviruses Nucleocapsid-specific T cells Limited protective function of spike-cross-reactive T cells Our results are thus consistent with, pre-existing non-spike cross-reactive memory T cells, protecting SARS-CoV-2-naïve contacts from infection, thereby supporting the inclusion of non-spike antigens in second-generation vaccines.

Show more
Show less